Is Vanda Pharmaceuticals Inc. (VNDA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.7% / 30% | 56.6% / 30% | 11.7% / 30% | 5.79% / 5% | ✗ NOT HALAL |
| DJIM | 2.7% / 33% | 56.6% / 33% | 11.7% / 33% | 5.79% / 5% | ✗ NOT HALAL |
| MSCI | 2.6% / 33% | 54.0% / 33% | 11.2% / 33% | 5.79% / 5% | ✗ NOT HALAL |
| S&P | 2.7% / 33% | 56.6% / 33% | 11.7% / 33% | 5.79% / 5% | ✗ NOT HALAL |
| FTSE | 2.6% / 33% | 54.0% / 33% | 11.2% / 50% | 5.79% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 94.0% | |
| Operating Margin | -70.5% | |
| Net Margin | -102.0% | |
| Return on Equity (ROE) | -50.9% | |
| Return on Assets (ROA) | -16.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$109M |
| Free Cash Flow | -$110M |
| Total Debt | $13M |
| Debt-to-Equity | 3.9 |
| Current Ratio | 2.4 |
| Total Assets | $489M |
Price & Trading
| Last Close | $7.12 |
| 50-Day MA | $7.74 |
| 200-Day MA | $5.83 |
| Avg Volume | 3.1M |
| Beta | 0.6 |
|
52-Week Range
$3.81
| |
About Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Vanda Pharmaceuticals Inc. (VNDA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Vanda Pharmaceuticals Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Vanda Pharmaceuticals Inc.'s debt ratio?
Vanda Pharmaceuticals Inc.'s debt ratio is 2.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.6%.
What are Vanda Pharmaceuticals Inc.'s key financial metrics?
Vanda Pharmaceuticals Inc. has a market capitalization of $408M, and revenue of $216M. The company maintains a gross margin of 94.0% and a net margin of -102.0%. Return on equity stands at -50.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.